# LINKER-MM1 (NCT03761108)

> Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03761108
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Regeneron Pharmaceuticals
- Conditions: Multiple Myeloma
- Interventions: Linvoseltamab
- Enrollment: 387
- Primary outcome: Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period
- Primary outcome: Incidence and severity of treatment-emergent adverse events (TEAEs)
- Primary outcome: Incidence and severity of adverse events of special interest (AESI)
- Primary outcome: Assessment of the pharmacokinetics (PK) of linvoseltamab
- Primary outcome: Concentrations of linvoseltamab in serum over time
- Primary outcome: Objective response rate (ORR) as determined by an Independent Review Committee (IRC)
- Primary outcome: Incidence and severity of cytokine release syndrome (CRS) with linvoseltamab
- Primary outcome: ORR of IV linvoseltamab as assessed by investigator

## Commentary we found

- YouTube: 40
- Podcasts: 22
- X threads: 11

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=linker-mm1-nct03761108

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03761108", "email": "<work email>"}; the inbox owner confirms by the emailed link.